Research progress on anticancer therapeutics targeting telomere/telomerase
10.3969/j.issn.1000-8179.2016.15.542
- VernacularTitle:靶向端粒端粒酶的抗肿瘤治疗研究进展
- Author:
Dong QIAN
;
Xiaofeng DING
;
Jingjing CHENG
;
Zhiyong YUAN
- Publication Type:Journal Article
- Keywords:
telomere;
telomerase;
tumor;
targeting therapy;
radiotherapy
- From:
Chinese Journal of Clinical Oncology
2016;43(15):679-682
- CountryChina
- Language:Chinese
-
Abstract:
Telomeres are protective caps located at the ends of human chromosomes. Telomeres shorten with each successive cell di-vision in normal human cells, whereas they are continuously elongated by human telomerase in over 85%of tumors. This simple and attractive difference steers the development of anticancer drugs targeting telomeres and telomerase. Many promising current telo-mere/telomerase-targeting agents, such as GRN163L and GV1001, showed good therapeutic effect both in preclinical studies and phaseⅠ/Ⅱclinical trials. These agents have even entered phaseⅢclinical trials in patients with various tumors. Most therapeutics are more effective when used in combination with standard chemotherapies. Moreover, pharmacological interference with tumor-cell telomere biology to reduce telomere length and/or telomere stability could enhance the effectiveness and safety of radiotherapy. Therapeutics targeting telomere/telomerase may play a key role in radiotherapy in the era of personalized medicine in the future.
